Created with sketchtool.

NERLYNX prevents recurrence1,*

DESCRIPTIVE ANALYSES: INVASIVE DISEASE-FREE SURVIVAL (iDFS) AT 5 YEARS IN HER2+, HR+ POPULATION PATIENTS COMPLETING PRIOR TRASTUZUMAB-BASED THERAPY ≤1 YEAR FROM RANDOMIZATION (n=1334)

iDFS chart

42% reduction in risk of recurrence*,†

95% of the patients with HER2+, HR+ disease had concomitant endocrine therapy.2

iDFS in the ITT population (N=2840): 94.2% with NERLYNX (95% CI: 92.6%, 95.4%) vs 91.9% with placebo (95% CI: 90.2%, 93.2%) at 2 years (HR=0.66; 95% CI: 0.49, 0.90; P=0.008)3

*Recurrence was defined as time from randomization to first occurrence of invasive ipsilateral tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, distant recurrence, or death from any cause.

Results of ExteNET are supported by an exploratory analysis of 5-year follow-up, with 74.5% (2117/2840) of patients reconsented.2

CI: confidence interval; HER: human epidermal growth factor receptor; HR: hazard ratio; HR+: hormone receptor-positive; ITT: intent-to-treat.

Select IMPORTANT SAFETY INFORMATION

Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.

Please see additional IMPORTANT SAFETY INFORMATION below.

Invasive disease-free survival (iDFS) benefit across several prespecified subgroups

ITT POPULATION: iDFS BENEFIT AT 2 YEARS, BY SUBGROUP21

CI: confidence interval; HR: hazard ratio; ITT: intent-to-treat.

Select IMPORTANT SAFETY INFORMATION

Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

Lactation: Advise women not to breastfeed.

Please see additional IMPORTANT SAFETY INFORMATION below.

NERLYNX prevents recurrence in patients who did not achieve a pCR1,*

DESCRIPTIVE ANALYSES: INVASIVE DISEASE-FREE SURVIVAL (iDFS) AT 5 YEARS IN HER2+ HR+ PATIENTS WHO COMPLETED PRIOR TRASTUZUMAB-BASED THERAPY ≤1 YEAR FROM RANDOMIZATION AND DID NOT ACHIEVE A pCR (n=295)

DDFS chart

40% reduction in risk of recurrence*,†

  • ExteNET was a pivotal phase 3, global, multicenter, randomized, double-blind, placebo-controlled study of NERLYNX 240 mg/day for 1 year (n=1420) vs placebo (n=1420) in patients with early-stage HER2+ breast cancer (N=2840). The primary endpoint in ExteNET was iDFS.2,3
  • iDFS in the ITT population (N=2840): 94.2% with NERLYNX (95% CI: 92.6%-95.4%) vs 91.9% with placebo (95% CI: 90.2%-93.2%) at 2 years (HR=0.66; 95% CI: 0.49-0.90; P=0.008)3

*Recurrence is defined as the time from randomization to first occurrence of invasive ipsilateral tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, distant recurrence, or death from any cause.

Results of ExteNET are supported by descriptive analyses after 5 years of follow-up, with 74.5% of patients (2117/2840) reconsented. 95% of the patients with HER2+ HR+ disease had concomitant endocrine therapy. Data in HER2+ HR+ patients who did not achieve a pCR were derived from a descriptive subgroup analysis.2

CI: confidence interval; HER: human epidermal growth factor receptor; HR: hazard ratio; HR+: hormone receptor–positive; ITT: intent-to-treat; pCR: pathologic complete response.

Select IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS:

The most common adverse reactions (reported in ≥5% of patients) were:

  • NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.

Please see additional IMPORTANT SAFETY INFORMATION below.

NERLYNX increases overall survival (OS) in patients who did not achieve a pCR1

DESCRIPTIVE ANALYSES: OS AT 8 YEARS IN HER2+ HR+ PATIENTS WHO COMPLETED PRIOR TRASTUZUMAB-BASED THERAPY ≤1 YEAR FROM RANDOMIZATION AND DID NOT ACHIEVE A pCR (n=295)*

iDFS chart

53% reduction in risk of death*

  • 2.1% absolute benefit in OS at 8 years vs placebo in HER2+ HR+ patients who completed prior trastuzumab-based therapy ≤1 year from randomization (n=1334) (HR=0.79; 95% CI: 0.55-1.13)
  • After a median follow-up of 8 years there was no statistically significant difference in OS between NERLYNX and placebo (HR=0.95; 95% CI: 0.75-1.21). The 5-year estimate of OS was 94.1% (95% CI: 92.7%-95.3%) with NERLYNX and 93.3% (95% CI: 91.8%-94.5%) with placebo3

*95% of the patients with HER2+ HR+ disease had concomitant endocrine therapy. Data in HER2+ HR+ patients who did not achieve a pCR were derived from a descriptive subgroup analysis.1,2

CI: confidence interval; HER: human epidermal growth factor receptor; HR: hazard ratio; HR+: hormone receptor–positive; pCR: pathologic complete response.

Select IMPORTANT SAFETY INFORMATION

Drug interactions: 1. Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. When patients require gastric acid reducing agents, use an H2-receptor antagonist or antacid. Separate NERLYNX by at least 3 hours with antacids. Separate NERLYNX by at least 2 hours before or 10 hours after H2-receptor antagonists. 2. Strong CYP3A4 inhibitors: Avoid concomitant use. 3. Moderate CYP3A4 and P-glycoprotein (P-gp) dual inhibitors: Avoid concomitant use. 4. Strong or moderate CYP3A4 inducers: Avoid concomitant use. 5. P-glycoprotein (P-gp) substrates: Monitor for adverse reactions of narrow therapeutic agents that are P-gp substrates when used concomitantly with NERLYNX.

Please see additional IMPORTANT SAFETY INFORMATION below.

NERLYNX prevents CNS metastases in patients who did not achieve a pCR1

DESCRIPTIVE ANALYSES: HER2+ HR+ PATIENTS COMPLETING PRIOR TRASTUZUMAB-BASED THERAPY ≤1 YEAR FROM RANDOMIZATION WHO DID NOT ACHIEVE A pCR (n=295)*

0.8% (95% CI: 0.1%-4.0%) of patients (n=131) experienced CNS recurrence as the first site of metastases with NERLYNX vs 3.6% (95% CI: 1.3%-7.8%) of patients (n=164) with placebo.

76% reduction in the risk of CNS recurrence or death from any cause 98.4% (95% CI: 93.6%-99.6%) of patients (n=131) experienced CNS-DFS at 5 years with NERLYNX vs 92.0% (95% CI: 85.6%-95.7%) of patients (n=164) with placebo (HR=0.24; 95% CI: 0.04-0.92).

*Results of ExteNET are supported by descriptive analyses after 5 years of follow-up, with 74.5% of patients (2117/2840) reconsented. Data in HER2+ HR+ patients who did not achieve a pCR were derived from a descriptive subgroup analysis.1,2

CI: confidence interval; CNS: central nervous system; CNS-DFS: central nervous system disease-free survival; HER: human epidermal growth factor receptor; HR: hazard ratio; HR+: hormone receptor–positive; pCR: pathologic complete response.

Select IMPORTANT SAFETY INFORMATION

Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.

Please see additional IMPORTANT SAFETY INFORMATION below.

Learn about adverse events

IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥5% of patients) were:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

For Full Prescribing Information, please click here.